Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.62 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353413 | 1.00 | BACE1 (0.62) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL30353445 | 1.00 | BACE1 (0.62) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL1804321 | 1.00 | BACE1 (0.62) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL16848342 | 0.85 | MIF (0.64) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL16848343 | 0.85 | MIF (0.64) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL31158251 | 0.85 | MIF (0.64) | BACE1MIFAKR1C3AKR1C2EIF2AK2 | |
| SCHEMBL18075746 | 0.84 | BACE1 (0.60) | BACE1MIFTYRALDH1A1MAPT | |
| SCHEMBL1647148 | 0.84 | BACE1 (0.85) | BACE1AKR1B10AKR1B1ALDH1A1MAPT | |
| SCHEMBL1647145 | 0.84 | BACE1 (0.85) | BACE1AKR1B10AKR1B1ALDH1A1MAPT | |
| SCHEMBL30353444 | 0.84 | BACE1 (0.60) | BACE1MIFTYRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| CN-109661387-B | Composition for treating pulmonary fibrosis | 维克图斯生物系统有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2022-08-02 | — | — | US | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-02-16 | — | — | US | disclosed |
| EP-3271326-B1 | COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE | VECTUS BIOSYSTEMS LTD (AU) | 2020-10-28 | — | — | EP | disclosed |
| CN-107614484-B | Composition for treating kidney and/or liver diseases | 维克图斯生物系统有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| EP-2496544-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | Fibrostatin, S.L. (SE) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| EP-0028063-B1 | PHENOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-06-13 | — | — | EP | disclosed |
| EP-0028063-A1 | Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885 |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | BACE1 4100/4885MIF 243/4885AKR1C3 2082/4885 |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | BACE1 4100/4885MIF 243/4885AKR1C3 2082/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885 |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | BACE1 4100/4885MIF 243/4885AKR1C3 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.